FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213141977> ?p ?o ?g. }

• W3213141977 endingPage "2582" @default.
• W3213141977 startingPage "2582" @default.
• W3213141977 abstract "Abstract Background: Activation of extracellular-signal regulated kinase (ERK) is almost universal in histiocytic disorders and is driven by genomic alterations in the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinases (PI3K) pathways. While BRAFV600E mutations are well described in histiocytic disorders, less is known about BRAF fusions. The goal of our study is to describe the frequency and clinical characteristics of patients harboring BRAF fusions. Methods: We included patients with a diagnosis of histiocytic disorder seen at our institution from November 2016-June 2021. Only those who had adequate BRAF testing were included. The following were considered adequate BRAF testing: 1) unequivocally positive BRAF V600E immunostain with or without molecular confirmation; 2) successful multigene next generation sequencing (mostly Tempus â or FoundationOne â) if BRAF V600Eimmunostain was equivocal or negative. We also searched the literature for similar cases and compared BRAF fusions found in histiocytic disorders to those found in solid tumors and other hematologic conditions. Results: One hundred and twenty-six patients were included in this study. BRAF fusions were detected in 7 (6%) patients. The median follow-up for these patients was 1.4 years (95% CI: 0.4-not reached). The frequency according to disease subtypes is as follows: Erdheim-Chester disease (ECD; 2/46 [4%]), Langerhans cell histiocytosis (LCH; 1/41 [2%]), adult or juvenile xanthogranuloma (AXG/JXG; 4/7 [57%]), and histiocytic or Langerhans cell sarcoma (HS/LCS; 0/9 [0%]). The median age at diagnosis for our study cohort was 34 years (range, 7-81 years) and 5 were females. The clinical characteristics and nature of BRAF fusions of our 7 patients plus additional 13 cases from the literature are shown in Table 1. For the final cohort of 20 patients with BRAF-fusions, the median age was 16 years (range, 0.5-81 years) and most (56%) were females. The distribution by histiocytic subtypes is as follows: AXG/JXG (45%), LCH (40%), ECD (10%), HS/LCS (5%). Two patients received cobimetinib as frontline treatment in our cohort and achieved partial responses. Of these two patients, one completed 12 cycles (12 months) of cobimetinib and had a sustained PR while the other patient received 2 cycles before having to hold therapy due to intolerable adverse effects despite dose reduction. From literature review, another patient (LR-12) received cobimetinib as second line treatment and achieved complete response. We found 15 unique BRAF gene fusions with 4 being recurrent. Except for AGAP3-BRAF, none of these BRAF fusions in histiocytosis has been reported in solid tumors or hematologic conditions to date. Conclusions: BRAF gene fusions occur rarely (&lt;5%) in histiocytic disorders. The only exception is AXG/JXG where more than half of the patients harbor BRAF gene fusions. These gene fusions are mostly distinct to histiocytosis and not found in solid tumors or other hematologic conditions. Figure 1 Figure 1. Disclosures Bennani: Purdue Pharma: Other: Advisory Board; Daichii Sankyo Inc: Other: Advisory Board; Kyowa Kirin: Other: Advisory Board; Vividion: Other: Advisory Board; Kymera: Other: Advisory Board; Verastem: Other: Advisory Board." @default.
• W3213141977 created "2021-11-22" @default.
• W3213141977 creator A5010727520 @default.
• W3213141977 creator A5020872528 @default.
• W3213141977 creator A5029802364 @default.
• W3213141977 creator A5056210769 @default.
• W3213141977 creator A5058645403 @default.
• W3213141977 creator A5069952110 @default.
• W3213141977 creator A5070939659 @default.
• W3213141977 creator A5076071872 @default.
• W3213141977 creator A5082158405 @default.
• W3213141977 creator A5088357128 @default.
• W3213141977 creator A5090092577 @default.
• W3213141977 date "2021-11-05" @default.
• W3213141977 modified "2023-10-18" @default.
• W3213141977 title "BRAF Fusions in Histiocytic Disorders: Frequency and Clinical Characteristics" @default.
• W3213141977 doi "https://doi.org/10.1182/blood-2021-149802" @default.
• W3213141977 hasPublicationYear "2021" @default.
• W3213141977 type Work @default.
• W3213141977 sameAs 3213141977 @default.
• W3213141977 citedByCount "1" @default.
• W3213141977 countsByYear W32131419772022 @default.
• W3213141977 crossrefType "journal-article" @default.
• W3213141977 hasAuthorship W3213141977A5010727520 @default.
• W3213141977 hasAuthorship W3213141977A5020872528 @default.
• W3213141977 hasAuthorship W3213141977A5029802364 @default.
• W3213141977 hasAuthorship W3213141977A5056210769 @default.
• W3213141977 hasAuthorship W3213141977A5058645403 @default.
• W3213141977 hasAuthorship W3213141977A5069952110 @default.
• W3213141977 hasAuthorship W3213141977A5070939659 @default.
• W3213141977 hasAuthorship W3213141977A5076071872 @default.
• W3213141977 hasAuthorship W3213141977A5082158405 @default.
• W3213141977 hasAuthorship W3213141977A5088357128 @default.
• W3213141977 hasAuthorship W3213141977A5090092577 @default.
• W3213141977 hasBestOaLocation W32131419771 @default.
• W3213141977 hasConcept C126322002 @default.
• W3213141977 hasConcept C142724271 @default.
• W3213141977 hasConcept C2777484599 @default.
• W3213141977 hasConcept C2777578932 @default.
• W3213141977 hasConcept C2779134260 @default.
• W3213141977 hasConcept C2779945361 @default.
• W3213141977 hasConcept C2780174970 @default.
• W3213141977 hasConcept C43100952 @default.
• W3213141977 hasConcept C71924100 @default.
• W3213141977 hasConceptScore W3213141977C126322002 @default.
• W3213141977 hasConceptScore W3213141977C142724271 @default.
• W3213141977 hasConceptScore W3213141977C2777484599 @default.
• W3213141977 hasConceptScore W3213141977C2777578932 @default.
• W3213141977 hasConceptScore W3213141977C2779134260 @default.
• W3213141977 hasConceptScore W3213141977C2779945361 @default.
• W3213141977 hasConceptScore W3213141977C2780174970 @default.
• W3213141977 hasConceptScore W3213141977C43100952 @default.
• W3213141977 hasConceptScore W3213141977C71924100 @default.
• W3213141977 hasIssue "Supplement 1" @default.
• W3213141977 hasLocation W32131419771 @default.
• W3213141977 hasOpenAccess W3213141977 @default.
• W3213141977 hasPrimaryLocation W32131419771 @default.
• W3213141977 hasRelatedWork W2027620575 @default.
• W3213141977 hasRelatedWork W2078886881 @default.
• W3213141977 hasRelatedWork W2103701567 @default.
• W3213141977 hasRelatedWork W244065325 @default.
• W3213141977 hasRelatedWork W2483143318 @default.
• W3213141977 hasRelatedWork W2559368399 @default.
• W3213141977 hasRelatedWork W2605722627 @default.
• W3213141977 hasRelatedWork W3114637510 @default.
• W3213141977 hasRelatedWork W3213141977 @default.
• W3213141977 hasRelatedWork W4362522465 @default.
• W3213141977 hasVolume "138" @default.
• W3213141977 isParatext "false" @default.
• W3213141977 isRetracted "false" @default.
• W3213141977 magId "3213141977" @default.
• W3213141977 workType "article" @default.